Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$69.6 million.

  • ImmunityBio's Free Cash Flow rose 3073.65% to -$69.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$324.8 million, marking a year-over-year increase of 2517.81%. This contributed to the annual value of -$398.1 million for FY2024, which is 19.71% down from last year.
  • Per ImmunityBio's latest filing, its Free Cash Flow stood at -$69.6 million for Q3 2025, which was up 3073.65% from -$80.9 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Free Cash Flow ranged from a high of -$67.6 million in Q1 2021 and a low of -$123.2 million during Q4 2023
  • Moreover, its 5-year median value for Free Cash Flow was -$93.1 million (2023), whereas its average is -$92.5 million.
  • As far as peak fluctuations go, ImmunityBio's Free Cash Flow plummeted by 11829.09% in 2021, and later surged by 3073.65% in 2025.
  • ImmunityBio's Free Cash Flow (Quarter) stood at -$82.0 million in 2021, then tumbled by 33.66% to -$109.7 million in 2022, then fell by 12.37% to -$123.2 million in 2023, then rose by 29.19% to -$87.3 million in 2024, then rose by 20.19% to -$69.6 million in 2025.
  • Its Free Cash Flow was -$69.6 million in Q3 2025, compared to -$80.9 million in Q2 2025 and -$87.0 million in Q1 2025.